<DOC>
	<DOCNO>NCT01599728</DOCNO>
	<brief_summary>Despite modern advance treatment , heart failure continue carry poor prognosis high morbidity mortality rate . Hence , remain major interest development novel therapeutic agent debilitate condition . Urocortins recently shoot limelight potential role pathophysiology treatment heart failure . Recent study investigator group ( REC : 09/S1103/41 ) confirm Urocortin 2 3 potent arterial vasodilator , effect reproducible well tolerate healthy male volunteer . Previous study use heart failure model animals1-7 , well study heart failure patient ( Urocortin 2 ) , suggest great scope Urocortins novel biomarkers potential therapeutic agent heart failure . With mind , investigator wish study local vasomotor effect peptides great detail patient heart failure .</brief_summary>
	<brief_title>Effect Urocortins Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<criteria>Patients heart failure : 1 . Patients stable heart failure ( NYHA class IIIV ) maximum tolerated dos ACE inhibitor betablocker least 3 month . 2 . Baseline echocardiographic parameter ( echo perform within last 12 month ) recruitment : ejection fraction ( EF ) &lt; 35 % , leave ventricular end dimension &gt; 5.5cm fractional shorten &lt; 20 % 3 . Age 1880 year ( inclusive ) recruitment Healthy volunteer : Age sexmatched healthy volunteer 1 . Lack inform consent 2 . Age &lt; 18 year &gt; 80 year 3 . Current involvement clinical trial 4 . Systolic blood pressure &gt; 190 mmHg &lt; 90 mmHg , untreated malignant arrhythmia 5 . Haemodynamically significant valvular heart disease 6 . Severe significant comorbidity include bleed diathesis , renal hepatic failure 7 . History anaemia 8 . Recent infective/inflammatory condition 9 . Recent blood donation ( prior 3 month ) 10 . Women child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Urocortin 2</keyword>
	<keyword>Urocortin 3</keyword>
	<keyword>Forearm venous occlusion plethysmography</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Substance P</keyword>
</DOC>